[CONSOLIDATION_METHOD_TITLE] [CONSOLIDATION_METHOD]
Related Companies
[]
Related Funds
[]
English
oda_NewBusinessRelationAbstract|
New Business Relation
oda_UpdateAnnouncementFlag|
Update Notification Flag
Hayır (No)
oda_CorrectionAnnouncementFlag|
Correction Notification Flag
Hayır (No)
oda_DateOfThePreviousNotificationAboutTheSameSubject|
Date Of The Previous Notification About The Same Subject
-
oda_DelayedAnnouncementFlag|
Postponed Notification Flag
Hayır (No)
oda_AnnouncementContentSection|
Announcement Content
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
Nature Of The Other Party With Which New Business Relation Will Start
Tedarikçi (Supplier)
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
Name Surname Or Company Title Of Customer Or Supplier
Sanovel İlaç Sanayi ve Ticaret A.Ş.
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
If Exists Share Of Customer Or Supplier In Net Sales Or Cost Of Goods Sold On Latest Disclosed Profit Or Loss And Other Comprehensive Income Statement Of Company
-
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
If Exists Share Of Customer Or Supplier In Trade Receivables Or Debts On Latest Disclosed Statement of Financial Position Of Company
-
oda_ExpectedStartingDateOfNewBusinessRelation|
Expected Starting Date O fNew Business Relation
16/11/2021
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
If Exist Significant Provisions Of The Contract
-
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
Impact Of New Business Relation On Company Activities
It will have positive impact on Company's activities on a global basis.
oda_ExplanationSection|
Explanations
oda_ExplanationTextBlock|

-Unofficial Translation-

Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. ("Gen") and Sanovel İlaç Sanayi ve Ticaret A.Ş. ("Sanovel") signed a license and supply agreement ("Agreement") on 16.11.2021 that will enter into force on the date of signature. In accordance with the Agreement sale and distribution of the medicines produced by Sanovel and subjected to the Agreement will be carried out by our Company in Azerbaijan and Uzbekistan.

The medicines within the scope of the Agreement are Ticagrelor used in the treatment of acute coronary diseases, Nebivalol used in the treatment of hypertension and coronary failure, and Dimetyl Fumarate used in the treatment of Multiple Sclerosis diseases.

The agreement is signed for a period of 10 years at the first stage, and the contribution of this Agreement to our Company's sales is 50,500 boxes and approximately USD 950,000 (TL 9,500,000) for 2022, 86,000 boxes and approximately USD 1,350,000 (TL 13,500,000) for 2023 and 2024. 123.500 boxes and approximately USD 1.840.000 (TL 18.400.000). These numbers indicate that only contributions to the Company's sales on Azerbaijan market, numbers for Uzbekistan market will  be determined in future.

In addition, with this agreement, the efficiency of our Company in the Azerbaijan and Uzbekistan markets will be increased and the agreement will have a positive impact on our activities on a global basis.